Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 21742554)

1.

Evolution of platinum resistance in high-grade serous ovarian cancer.

Cooke SL, Brenton JD.

Lancet Oncol. 2011 Nov;12(12):1169-74. doi: 10.1016/S1470-2045(11)70123-1.

PMID:
21742554
2.

The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.

Ng CK, Cooke SL, Howe K, Newman S, Xian J, Temple J, Batty EM, Pole JC, Langdon SP, Edwards PA, Brenton JD.

J Pathol. 2012 Apr;226(5):703-12. doi: 10.1002/path.3980. Epub 2012 Feb 9.

PMID:
22183581
3.

Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.

Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A.

J Pathol. 2012 Apr;226(5):746-55. doi: 10.1002/path.3035. Epub 2012 Jan 17. Erratum in: J Pathol. 2014 Feb;232(3):e1.

4.

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.

Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ.

Gynecol Oncol. 2009 Jul;114(1):48-52. doi: 10.1016/j.ygyno.2009.03.001. Epub 2009 Apr 10.

PMID:
19361839
5.

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.

Baumann KH, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, Kurzeder C, Hilpert F, Hasenburg A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D, Wagner U.

Ann Oncol. 2012 Sep;23(9):2265-71. doi: 10.1093/annonc/mds003. Epub 2012 Feb 29.

6.

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.

Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA.

BMC Cancer. 2013 Nov 16;13:549. doi: 10.1186/1471-2407-13-549.

7.

Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.

Fotopoulou C, Vergote I, Mainwaring P, Bidzinski M, Vermorken JB, Ghamande SA, Harnett P, Del Prete SA, Green JA, Spaczynski M, Blagden S, Gore M, Ledermann J, Kaye S, Gabra H.

Ann Oncol. 2014 Jan;25(1):160-5. doi: 10.1093/annonc/mdt515. Epub 2013 Dec 5.

8.

The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.

Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP.

Hum Pathol. 2015 Jan;46(1):1-8. doi: 10.1016/j.humpath.2014.10.004. Epub 2014 Oct 16.

PMID:
25455994
9.

Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance.

Pinato DJ, Graham J, Gabra H, Sharma R.

Cancer Treat Rev. 2013 Apr;39(2):153-60. doi: 10.1016/j.ctrv.2012.04.004. Epub 2012 May 16. Review.

PMID:
22595680
10.
11.

Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.

Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB.

Gynecol Oncol. 2014 Jun;133(3):591-8. doi: 10.1016/j.ygyno.2014.03.557. Epub 2014 Mar 20.

PMID:
24657486
12.

Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.

Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.

Oncology. 2013;84(3):158-65. doi: 10.1159/000341366. Epub 2012 Dec 28.

PMID:
23296063
13.

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM.

J Clin Oncol. 2007 Feb 10;25(5):517-25. Retraction in: J Clin Oncol. 2012 Feb 20;30(6):678.

14.

Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.

Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS.

J Clin Oncol. 2003 Aug 1;21(15):2856-9.

PMID:
12885801
15.

The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms.

Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W.

Oncol Res. 2010;18(7):343-7.

PMID:
20377136
16.

Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.

Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K, Kobayashi H, Otsuki Y, Nakayama S, Miyazaki K.

Mod Pathol. 2012 Feb;25(2):282-8. doi: 10.1038/modpathol.2011.161. Epub 2011 Nov 18.

17.

Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer.

Nguyen TT, Wright JD, Powell MA, Gibb RK, Rader JS, Allsworth JE, Mutch DG.

Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1194-9. doi: 10.1111/j.1525-1438.2007.01184.x. Epub 2008 Jan 23.

PMID:
18217964
18.

DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.

Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H, Gabra H.

Neoplasia. 2011 Nov;13(11):1069-80.

19.

Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.

Rauh-Hain JA, Nitschmann CC, Worley MJ Jr, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS.

Gynecol Oncol. 2013 Apr;129(1):63-8. doi: 10.1016/j.ygyno.2013.01.009. Epub 2013 Jan 18.

PMID:
23337490
20.

Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.

Goto T, Takano M, Ohishi R, Iwasa N, Shimizu M, Hasegawa K, Nagao S, Fujiwara K.

J Obstet Gynaecol Res. 2010 Aug;36(4):764-8. doi: 10.1111/j.1447-0756.2010.01217.x.

PMID:
20666942
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk